Skip to main content

Table 1 Characteristics of patients with immune checkpoint inhibitors in head and neck cancer

From: Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

  HNSCC (n = 35) NPC (n = 11)
Age (years) 57.8 (39–73) 47.4 (16–74)
Sex
Male 25 (71.4) 9 (81.8)
Female 10 (28.6) 2 (18.2)
Smoking
Current 7 (20.0) 3 (27.3)
Former 15 (42.9) 3 (27.3)
Never 13 (37.1) 5 (45.5)
ECOG
1 27 (77.1) 11 (100.0)
2 8 (22.9) 0 (0.0)
Primary tumor location Hypopharynx/Larynx 5 Nasopharynx 11
Oropharynx/Oral cavity 15   
Nasal cavity/Paranasal sinuses 12   
Others 3   
Histology SQ 32 (91.4) Non-keratinizing carcinoma 8 (72.7)
Others 3 (8.6) Others 3 (27.3)
  HPV (oropharynx/oral cavity) EBV
Positive 5 (33.3) 8 (72.7)
Negative 7 (46.7) 1 (9.1)
NA 3 (20.0) 2 (18.2)
PD-L1 22C3 (CPS)
  < 1 3 2
  ≥ 1 12 (≥ 20:8) 6 (≥ 20:3)
NA 20 3
Prior treatment
Surgery → CCRT/RT 14 (40.0) 0
CCRT/RT → Surgery 4 (11.4) 0
CCRT 10 (28.6) 6 (54.5)
RT 5 (14.3) 1 (9.1)
Induction chemotherapy 9 (25.7) 1 (9.1)
Adjuvant chemotherapy 1 (2.9) 2 (18.2)
Platinum-refractory
Yes 29 (82.9) 10 (90.9)
No 5 (14.3) 1 (9.1)
No exposure to platinum 1 (2.9) 0 (0.0)
Prior palliative chemotherapy lines 1 (0–4) 2 (1–4)
Prior Cetuximab + Platinum 13 (37.1) 0 (0.0)
Immunotherapy
Nivolumab 29 (82.9) 3 (27.3)
Pembrolizumab 6 (17.1) 8 (72.7)
No. of cycles 3 (1–19) 3 (1–24)
  1. Abbreviations: HNSCC head and neck squamous cell carcinoma, NPC nasopharyngeal cancer, ECOG Eastern Cooperative Oncology Group, SQ squamous cell carcinoma, HPV human papillomavirus, EBV Epstein–Barr virus, NA not available, CPS combined positive score, CCRT concurrent chemoradiotherapy